Slingshot members are tracking this event:

Novartis (NVS) Presents Phase 3 MONALEESA-2 Data Evaluating LEE011 + Femara in Patients with Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 09, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Monaleesa-2, Lee011, Femara, Hormone-receptor Positive, Hr+, Her2-, Advanced Breast Cancer, Metastatic Breast Cancer, Ribociclib